New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2)

Carlos J.A. Ribeiro, Jayakanth Kankanala, Ke Shi, Kayo Kurahashi, Evgeny Kiselev, Azhar Ravji, Yves Pommier, Hideki Aihara, Zhengqiang Wang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase II (TOP2) mediated DNA damages and causes resistance to TOP2-targeted cancer therapy. Inhibiting TDP2 could sensitize cancer cells toward TOP2 inhibitors. However, potent TDP2 inhibitors with favorable physicochemical properties are not yet reported. Therefore, there is a need to search for novel molecular scaffolds capable of inhibiting TDP2. We report herein a new simple, robust, homogenous mix-and-read fluorescence biochemical assay based using humanized zebrafish TDP2 (14M_zTDP2), which provides biochemical and molecular structure basis for TDP2 inhibitor discovery. The assay was validated by screening a preselected library of 1600 compounds (Z′ ≥ 0.72) in a 384-well format, and by running in parallel gel-based assays with fluorescent DNA substrates. This library was curated via virtual high throughput screening (vHTS) of 460,000 compounds from Chembridge Library, using the crystal structure of the novel surrogate protein 14M_zTDP2. From this primary screening, we selected the best 32 compounds (2% of the library) to further assess their TDP2 inhibition potential, leading to the IC50 determination of 10 compounds. Based on the dose-response curve profile, pan-assay interference compounds (PAINS) structure identification, physicochemical properties and efficiency parameters, two hit compounds, 11a and 19a, were tested using a novel secondary fluorescence gel-based assay. Preliminary structure-activity relationship (SAR) studies identified guanidine derivative 12a as an improved hit with a 6.4-fold increase in potency over the original HTS hit 11a. This study highlights the importance of the development of combination approaches (biochemistry, crystallography and high throughput screening) for the discovery of TDP2 inhibitors.

Original languageEnglish (US)
Pages (from-to)67-79
Number of pages13
JournalEuropean Journal of Pharmaceutical Sciences
StatePublished - Jun 15 2018

Bibliographical note

Funding Information:
This research was supported by the Academic Health Center Faculty Research Development Grant Program (FRD #14.23), University of Minnesota , and partially by the Center for Drug Design, University of Minnesota, and NIH grant GM118047 to HA. We thank Surajit Banerjee for his assistance during diffraction data collection at the Advanced Photon Source. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P41 GM103403). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. Studies performed by EK, AG and YP were supported by the Center for Cancer Research, the Intramural Program of the National Cancer Institute (Z001 BC006150).

Publisher Copyright:
© 2018 Elsevier B.V.


  • Anti-cancer
  • Fluorescence assay
  • Guanidines
  • High-throughput screening (HTS)
  • Tyrosyl-DNA phosphodiesterase 2 (TDP2)
  • Virtual screening


Dive into the research topics of 'New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2)'. Together they form a unique fingerprint.

Cite this